Pomalyst
Treats relapsed and refractory multiple myeloma by modulating the immune system and directly targeting tumour cells through cereblon binding, producing anti-proliferative, anti-angiogenic and immunomodulatory effects.
- Category
- Oncology Support
- Active ingredient
- Pomalidomide
- Route
- Oral use
- Form
- Capsule, hard
- Strengths
- 4mg
You will receive a quality generic equivalent of Pomalyst, depending on stock.
Prescription and consultation requirements for Pomalyst vary by destination and are determined by the fulfilment partner.
Pomalyst details
- Conditions
- Multiple Myeloma in Combination with Bortezomib and Dexamethasone in Adult Patients Who Have Received At Least One Prior Treatment Regimen Including Lenalidomide · Multiple Myeloma in Combination with Dexamethasone in Adult Patients with Relapsed and Refractory Disease Who Have Received At Least Two Prior Treatment Regimens Including Both Lenalidomide and Bortezomib and Have Demonstrated Disease Progression on The Last Therapy · Multiple Myeloma in Combination with Daratumumab and Dexamethasone in Adult Patients Who Have Received At Least One Prior Therapy · Multiple Myeloma in Combination with Isatuximab and Dexamethasone in Adult Patients Who Have Received At Least Two Prior Therapies Including Lenalidomide and A Proteasome Inhibitor
- Alternative names
- Imnovid
- Therapeutic class
- Immunosuppressants; Other immunosuppressants
- Pharmacological class
- Immunomodulatory imide drug; Cereblon e3 ubiquitin ligase modulator
- Dosage forms
- Capsule, hard
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Bristol-Myers Squibb Pharmaceuticals Limited
- Storage instructions
- Store below 25°C. Keep in the original blister package to protect from moisture.
Known off-label uses
primary central nervous system lymphoma; systemic light chain amyloidosis; myelofibrosis
Contraindications
hypersensitivity to pomalidomide or any excipient; women who are pregnant; women of childbearing potential unless all conditions of the pregnancy prevention programme are met
Precautions and warnings
pregnancy prevention programme mandatory for all patients; haematological toxicity including neutropenia, anaemia and thrombocytopenia requiring regular monitoring; venous thromboembolism risk requiring thromboprophylaxis; second primary malignancies; thyroid disorders including hypothyroidism; peripheral neuropathy; tumour lysis syndrome; cardiac disorders including myocardial infarction and cardiac failure; hepatic disorders; severe cutaneous reactions; allergic reactions including angioedema; risk of hepatitis b reactivation; dose adjustment required with strong cyp1a2 inhibitors; caution in patients with renal impairment requiring dose adjustment; caution in patients with hepatic impairment; progressive multifocal leukoencephalopathy reported; males must use condoms during treatment and for 7 days after discontinuation
Minor side effects
neutropenia; anaemia; thrombocytopenia; fatigue; pyrexia; peripheral oedema; nausea; diarrhoea; constipation; vomiting; decreased appetite; dyspnoea; cough; upper respiratory tract infection; pneumonia; back pain; bone pain; muscle spasms; arthralgia; peripheral neuropathy; headache; dizziness; tremor; rash; pruritus; insomnia; confusional state; hypercalcaemia; hypokalaemia; weight decreased; epistaxis
Moderate side effects
febrile neutropenia; severe thrombocytopenia with bleeding; deep vein thrombosis; pulmonary embolism; myocardial infarction; cardiac failure; atrial fibrillation; hepatic failure; stevens-johnson syndrome; toxic epidermal necrolysis; angioedema; tumour lysis syndrome; progressive multifocal leukoencephalopathy; hepatitis b reactivation; sepsis; pneumonia; acute kidney injury; pancreatitis
Serious side effects
signs of febrile neutropenia including fever, chills, sore throat, mouth ulcers, requires immediate medical attention; signs of venous thromboembolism including sudden chest pain, difficulty breathing, swelling or pain in one leg, requires immediate medical attention; signs of progressive multifocal leukoencephalopathy including confusion, vision changes, weakness on one side of body, requires immediate medical attention; signs of severe cutaneous reactions including widespread rash, blistering, peeling skin, requires immediate medical attention; signs of angioedema including swelling of face, lips, tongue or throat, requires immediate medical attention; signs of myocardial infarction including chest pain, shortness of breath, pain radiating to arm or jaw, requires immediate medical attention; signs of hepatic failure including jaundice, dark urine, confusion, abdominal swelling, requires immediate medical attention
Patient summary
Treats relapsed and refractory multiple myeloma by modulating the immune system and directly targeting tumour cells through cereblon binding, producing anti-proliferative, anti-angiogenic and immunomodulatory effects.
Mechanism of action
Pomalyst contains pomalidomide, a medicine belonging to a class of drugs called immunomodulatory imide drugs. It works by attaching to a protein called cereblon within cells. This binding changes how the cell functions, causing cancer cells to stop dividing and to die. Pomalidomide also stimulates the body's immune system to attack myeloma cells and prevents the formation of new blood vessels that tumours need to grow. It is used in adults with multiple myeloma whose cancer has come back after or did not respond to previous treatments.
Drug interactions
ciprofloxacin; enoxacin; fluvoxamine; warfarin; apixaban; rivaroxaban; dabigatran; heparin; digoxin; bortezomib; dexamethasone; daratumumab; isatuximab; simvastatin; atorvastatin; rosuvastatin; carbamazepine; phenytoin; rifampicin; st. john's wort; grapefruit juice
Age restrictions
Safety and efficacy in children and adolescents below 18 years have not been established.
Pregnancy and breastfeeding
Pomalidomide is contraindicated during pregnancy. It is structurally related to thalidomide and is expected to cause severe life-threatening birth defects. Women of childbearing potential must use effective contraception from at least 4 weeks before treatment, during treatment, and for at least 4 weeks after stopping. Breast-feeding must be discontinued during therapy.
What you will receive
Pomalyst is the originator brand name, made by Bristol-Myers Squibb Pharmaceuticals Limited. We use it to identify the medicine and are not affiliated with Bristol-Myers Squibb Pharmaceuticals Limited.
- The fulfilment partner confirms whether the exact brand or an equivalent containing Pomalidomide is offered.
- The offered brand, manufacturer and dispatch location depend on the product, destination and partner warehouse.
- Check the final product details at checkout before confirming an order.